Literature DB >> 10438342

Th2 responses to inactivated influenza virus can Be converted to Th1 responses and facilitate recovery from heterosubtypic virus infection.

T M Moran1, H Park, A Fernandez-Sesma, J L Schulman.   

Abstract

Immunization with live influenza virus expands Th1 memory cells and facilitates more rapid recovery after heterosubtypic virus challenge. Immunization with inactivated virus generates a Th2 response and does not lead to heterosubtypic immunity. Creation of a Th1 priming environment by the inclusion of interleukin (IL)-12 with antibodies to IL-4 converted the response against inactivated virus to a Th1 response that was able to facilitate virus clearance upon heterosubtypic virus challenge. Evaluation of memory responses of mice immunized by the various protocols demonstrated that the type of immunization imprints T cell memory, dictating the nature of the response to subsequent infection. After live virus challenge, expansion of Th1 cells seems to facilitate the generation of cytotoxic T lymphocytes from naïve precursors. This latter finding may be the mechanism by which inactivated virus immunization in a Th1 cytokine context mediates heterosubtypic immunity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10438342     DOI: 10.1086/314952

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  48 in total

1.  Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles.

Authors:  Jae-Min Song; Jaber Hossain; Dae-Goon Yoo; Aleksandr S Lipatov; C Todd Davis; Fu-Shi Quan; Li-Mei Chen; Robert J Hogan; Ruben O Donis; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2010-06-26       Impact factor: 3.616

2.  Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice.

Authors:  Tülin Morçӧl; Brett L Hurst; E Bart Tarbet
Journal:  Vaccine       Date:  2017-07-14       Impact factor: 3.641

3.  Vaccination with cell immunoglobulin mucin-1 antibodies and inactivated influenza enhances vaccine-specific lymphocyte proliferation, interferon-gamma production and cross-strain reactivity.

Authors:  W Soo Hoo; E R Jensen; A Saadat; D Nieto; R B Moss; D J Carlo; T Moll
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  A Novel R848-Conjugated Inactivated Influenza Virus Vaccine Is Efficacious and Safe in a Neonate Nonhuman Primate Model.

Authors:  Beth C Holbrook; Jong R Kim; Lance K Blevins; Matthew J Jorgensen; Nancy D Kock; Ralph B D'Agostino; S Tyler Aycock; Mallinath B Hadimani; S Bruce King; Griffith D Parks; Martha A Alexander-Miller
Journal:  J Immunol       Date:  2016-06-08       Impact factor: 5.422

5.  Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.

Authors:  Peter H Goff; Tomoko Hayashi; Luis Martínez-Gil; Maripat Corr; Brian Crain; Shiyin Yao; Howard B Cottam; Michael Chan; Irene Ramos; Dirk Eggink; Mitra Heshmati; Florian Krammer; Karen Messer; Minya Pu; Ana Fernandez-Sesma; Peter Palese; Dennis A Carson
Journal:  J Virol       Date:  2015-01-07       Impact factor: 5.103

6.  Estriol Reduces Pulmonary Immune Cell Recruitment and Inflammation to Protect Female Mice From Severe Influenza.

Authors:  Meghan S Vermillion; Rebecca L Ursin; Sarah E Attreed; Sabra L Klein
Journal:  Endocrinology       Date:  2018-09-01       Impact factor: 4.736

7.  Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens.

Authors:  Sang-Moo Kang; Lizheng Guo; Qizhi Yao; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  N-Glycosylation of Seasonal Influenza Vaccine Hemagglutinins: Implication for Potency Testing and Immune Processing.

Authors:  Yanming An; Lisa M Parsons; Ewa Jankowska; Darya Melnyk; Manju Joshi; John F Cipollo
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

9.  Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.

Authors:  Peter Aaby; Cesário L Martins; May-Lill Garly; Carlito Balé; Andreas Andersen; Amabelia Rodrigues; Henrik Ravn; Ida M Lisse; Christine S Benn; Hilton C Whittle
Journal:  BMJ       Date:  2010-11-30

10.  Intranasal delivery of influenza subunit vaccine formulated with GEM particles as an adjuvant.

Authors:  Vinay Saluja; Jean P Amorij; Maarten L van Roosmalen; Kees Leenhouts; Anke Huckriede; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2010-01-08       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.